On January 24, 2019 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body’s immune system to fight cancer, reported that the U.S. Patent and Trademark Office has issued a Notice of Allowance for the first patent covering Anixa subsidiary, Certainty Therapeutics, Inc.’s, CAR-T cancer treatment technology (Press release, Anixa Biosciences, JAN 24, 2019, View Source [SID1234532897]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The patent is titled "METHODS AND COMPOSITIONS FOR TREATING CANCER," and the inventors are Drs. Jose Conejo-Garcia and Alfredo Perales-Puchalt. Dr. Conejo-Garcia is the Chair of the Department of Immunology at Moffitt Cancer Center and Dr. Alfredo Perales-Puchalt is a Senior Postdoctoral Fellow in The Wistar Institute’s Vaccine & Immunotherapy Center. The patent is assigned to The Wistar Institute and Anixa Biosciences’ majority-owned subsidiary, Certainty Therapeutics, Inc. is the exclusive, world-wide licensee.
Dr. Amit Kumar, President and CEO of Anixa Biosciences, stated, "This is a ground-breaking patent protecting our CAR-T cancer technology. This technology takes advantage of specific hormone–hormone receptor biology to address malignancies and may hold promise to be the first successful CAR-T therapy against solid tumors. While our initial focus is the treatment of ovarian cancer, the technology covered by the patent is broad and may also be effective in treating other solid tumors by exploiting an anti-angiogenesis mechanism of action."
Dr. Kumar continued, "We are pleased that our licensor and shareholder in Certainty Therapeutics, Inc., The Wistar Institute, has received this Notice of Allowance, as this patent will offer intellectual property protection for the commercialization of this CAR-T solid tumor therapy. We have other filings at various stages of prosecution, and we hope to be receiving additional patents."
"We take seriously our collaborative efforts in protecting intellectual property that is critical for the advancement of new therapies, such as Anixa’s CAR-T therapy," said Heather Steinman, PhD, MBA, Vice President of Business Development at The Wistar Institute. "We are fully aligned with Anixa to ensure that Wistar’s technology may one day be used to help cancer patients."